✦ LIBER ✦

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

✍ Scribed by Renate E. van Genugten; Daniël H. van Raalte; Michaela Diamant

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The development of non-peptide glucagon-

✍ Ho-Sang Moon; Mi-Kyung Kim; Moon-Ho Son 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 620 KB

A glucagon-like peptide-1 (GLP-1) recept

✍ S. K. Thondam; D. J. Cuthbertson; B. S. Aditya; I. A. MacFarlane; J. P. Wilding; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

Incretin-based Therapies (Glucagon-like

✍ Amir Hanna; Vincent Woo; Jean-François Yale; Elaine M. Cooke 📂 Article 📅 2012 🏛 Canadian Diabetes Association 🌐 English ⚖ 208 KB

Glycaemic efficacy of glucagon-like pept

✍ C. F. Deacon; E. Mannucci; B. Ahrén 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 559 KB

Efficacy and Safety of Long-Acting Gluca

✍ Pinelli, N. R.; Hurren, K. M. 📂 Article 📅 2011 🏛 Harvey Whitney Books Company 🌐 English ⚖ 278 KB

Weight loss with liraglutide, a once-dai

✍ J. Jendle; M. A. Nauck; D. R. Matthews; A. Frid; K. Hermansen; M. Düring; M. Zdr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB